Paper
0
Nirsevimab and Hospitalization for RSV Bronchiolitis
Authors
Zein Assad,Anne-Sophie Romain
Camille Aupiais,Mickaël Shum,Cécile Schrimpf,Mathie Lorrot,Harriet Corvol,Blandine Prévost,Charlène Ferrandiz,Anna Giolito,Zaba Valtuille,Matthieu Bendavid,Jérémie Cohen,Julie Toubiana,Loïc Pontual,Camille Delande,Michael Levy,Perrine See,Robert Cohen,Corinne Lévy,François Angoulvant,Léa Lenglart,Maud Gits‐Muselli,Valérie Biran,Kadiatou Diallo,Oluwafunmilola Alemede,Mohamed Hebil,Xavier Durrmeyer,Géraldine Labouret,Natacha Casanovas,Benjamin Hallak,Olympe Maréchal,Camille Jung,C. Bréhin
+32 authors
,Naïm OuldaliPublished
Jul 10, 2024
Show more
Save
Tip0
TipSave
Abstract
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.